| Name | Title | Contact Details |
|---|
Consulting Engineers & Scientists, Inc. is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
LEARN Behavioral is a national organization that specializes in providing tailored treatment programs for children and young adults with autism spectrum disorder (ASD). We use contemporary applied behavior analysis (ABA) therapy that is based on the un...
New England Institutional Review Board NEIRB is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The mission of Codman Square Health Center is to serve as a resource for improving the physical, mental and social well-being of the community. Codman Square Health Center is an award-winning, community-based, outpatient health care and multi-service center in the heart of Dorchester. We opened our doors in 1979 with a dream: to build the best urban community in America. With a holistic and partnership-oriented approach, we ensure access to quality health care and other supportive services through a highly successful integrated model.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.